APP and Alzheimer disease: On the other hand, the loss of peripheral insulin (due to streptozotocin treatment) in a mouse model of AD, the APP/PS1 mouse, associates with increased production of amyloid β (Aβ) in brain, contributing to the pathological features of AD.